Outcome Of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated With Various Frontline Second-Generation Tyrosine Kinase Inhibitors: A Single-Center Experience

Background: The efficacy of second-generation tyrosine kinase inhibitors (2G-TKI) as frontline therapy for newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase (CP) has been established. 2G-TKI treated patients achieved faster and deeper molecular responses compared with imatinib (IM) treated patients. Because CML patients currently have multiple treatment options, their impact on long-term outcomes needs to be determined and each agent should be chosen with a consideration of distinct toxicity profile and patient's comorbidities. The aim of this study is to provide a comprehensive analysis of the outcome of CML patients treated with different 2G-TKIs and to explore contributing factors on the outcome, as additional information to guide clinical decisions on selecting a frontline therapy.